IMAGE CREDITS: COREWIRE / AI ILLUSTRATION

Growing this fast used to be impossible

The 18-month sprint to $100 million, the margin split that sorts survivors, and JPMorgan’s quiet endorsement.

SaaS took seven years to mint a $100 million company. AI does it in 18 months, and this week showed both what that speed buys and what it hides. The sorting has begun.

The 18-month sprint

Bessemer’s data tracks “supernova” startups averaging $40 million in revenue their first year and $125 million by year two. The old benchmarks did not bend. They snapped. See the cohort →

AI startups hit 100M ARR in 18 months

Speed is not health

But revenue velocity hides a split. Thin model wrappers run 25 percent gross margins; products that own their economics run 60 to 80. Same headlines, opposite fates. Which is which →

AI software margins separate winners

Proof beats pitch decks

The healthiest signal this week was not a valuation. It was JPMorgan physically deploying SambaNova’s chips for on-prem inference, the detail that explains the $1 billion round around it. Why it matters →

The customers became investors

Norm Ai went one better: it raised $120 million with Vanguard, TIAA and New York Life on the cap table, the same institutions its compliance agents are built to serve. Your buyer owning your equity is a very specific kind of validation. Read the round →

Open models found a banker too

And the open-weight economy got its own proof point: Together AI raised $800 million at $8.3 billion, claiming over $1.15 billion in annual bookings. Openness, it turns out, invoices just fine. The numbers →

One number

25 percent. The gross margin of a thin AI wrapper. Growth headlines expire; margins are forever. The full split →

One thing to watch

Mercor buying Deeptune. A CEO acquiring a startup he personally angel-funded three months ago. Velocity and governance are about to have a conversation. The deal →

That is the thread: the money moves faster than ever, and the margin decides who keeps any of it. Hit reply with the company you want audited next. Forwarded this? Claim your own copy.

Dr. Joseph Joshua

P.S. Next issue: the drug ads are for software now.

Get the Signal

AI and business tech news, verified by a physician who reads the filings. One email a week, no noise.

Dr. Joseph Joshua

Dr. Joseph Joshua is the founder and editor of Corewire. A medical doctor by training, he brings the evidence-first discipline of clinical medicine to technology journalism: claims get checked against primary sources before they get published. He has produced technology and B2B content for companies across…

View Bio

Keep Reading